Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Has Average Target Price of $20.72

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have been assigned a consensus rating of “Hold” from the twenty-three brokerages that are currently covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a sell rating, eight have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $20.72.

A number of research analysts have weighed in on the company. Wedbush raised their price objective on Intellia Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Wednesday, September 9th. Citizens Jmp reaffirmed a “market outperform” rating and set a $30.00 target price on shares of Intellia Therapeutics in a research note on Wednesday, September 9th. Wolfe Research lowered shares of Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 target price for the company. in a report on Wednesday, July 15th. Citigroup reaffirmed a “market outperform” rating on shares of Intellia Therapeutics in a report on Tuesday, August 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Thursday.

Institutional Trading of Intellia Therapeutics

A number of hedge funds have recently bought and sold shares of NTLA. PNC Financial Services Group Inc. lifted its stake in Intellia Therapeutics by 36.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,552 shares of the company’s stock worth $46,000 after purchasing an additional 948 shares in the last quarter. Wealthfront Advisers LLC grew its position in shares of Intellia Therapeutics by 7.6% in the first quarter. Wealthfront Advisers LLC now owns 14,450 shares of the company’s stock valued at $185,000 after purchasing an additional 1,018 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Intellia Therapeutics by 2.7% in the second quarter. Wellington Management Group LLP now owns 43,484 shares of the company’s stock valued at $736,000 after purchasing an additional 1,125 shares in the last quarter. Axxcess Wealth Management LLC grew its position in shares of Intellia Therapeutics by 6.1% in the first quarter. Axxcess Wealth Management LLC now owns 22,707 shares of the company’s stock valued at $291,000 after purchasing an additional 1,308 shares in the last quarter. Finally, Cyndeo Wealth Partners LLC grew its position in shares of Intellia Therapeutics by 6.1% in the third quarter. Cyndeo Wealth Partners LLC now owns 26,986 shares of the company’s stock valued at $325,000 after purchasing an additional 1,556 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $11.42 on Friday. The company has a market cap of $1.60 billion, a PE ratio of -3.40 and a beta of 1.80. The stock’s 50 day simple moving average is $12.27 and its 200-day simple moving average is $13.16. Intellia Therapeutics has a 1-year low of $7.95 and a 1-year high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, hitting the consensus estimate of ($0.80). Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%. The firm had revenue of $7.66 million during the quarter, compared to analysts’ expectations of $12.98 million. During the same period in the previous year, the business earned ($0.98) earnings per share. The firm’s revenue for the quarter was down 46.4% on a year-over-year basis. On average, equities research analysts anticipate that Intellia Therapeutics will post -3.21 EPS for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a biotechnology company focused on developing genome-editing therapies using CRISPR/Cas9 technology. The company is working to create treatments that can directly modify disease-causing genes, including through in vivo approaches in which the editing machinery is delivered into a patient’s body.

Its pipeline has included NTLA-2001, an investigational therapy designed to reduce production of transthyretin for the treatment of transthyretin amyloidosis, and NTLA-2002, an investigational program targeting kallikrein for hereditary angioedema.